EP0695356A1 - Cloning, expression and vaccine composition corresponding to a peptide antigen of toxoplasma gondii - Google Patents
Cloning, expression and vaccine composition corresponding to a peptide antigen of toxoplasma gondiiInfo
- Publication number
- EP0695356A1 EP0695356A1 EP94915540A EP94915540A EP0695356A1 EP 0695356 A1 EP0695356 A1 EP 0695356A1 EP 94915540 A EP94915540 A EP 94915540A EP 94915540 A EP94915540 A EP 94915540A EP 0695356 A1 EP0695356 A1 EP 0695356A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antigen
- gondii
- cell
- polypeptide
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 61
- 108091007433 antigens Proteins 0.000 title claims abstract description 61
- 102000036639 antigens Human genes 0.000 title claims abstract description 61
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 35
- 241000223997 Toxoplasma gondii Species 0.000 title claims abstract description 24
- 229960005486 vaccine Drugs 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 title claims description 6
- 238000010367 cloning Methods 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 22
- 229920001184 polypeptide Polymers 0.000 claims abstract description 16
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 9
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 108020004414 DNA Proteins 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 14
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 9
- 108091026890 Coding region Proteins 0.000 claims description 8
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 208000007089 vaccinia Diseases 0.000 claims description 6
- 230000000977 initiatory effect Effects 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 22
- 239000012634 fragment Substances 0.000 description 21
- 238000010276 construction Methods 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- -1 benzyl ester Chemical class 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102100031673 Corneodesmosin Human genes 0.000 description 4
- 101710139375 Corneodesmosin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100027377 HBS1-like protein Human genes 0.000 description 2
- 101001009070 Homo sapiens HBS1-like protein Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- SXTAYKAGBXMACB-UHFFFAOYSA-N methionine sulfoximine Chemical compound CS(=N)(=O)CCC(N)C(O)=O SXTAYKAGBXMACB-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GEXHAQTYBSQXEF-UHFFFAOYSA-N (2-methylpropan-2-yl)oxycarbonyl 2,2,2-trifluoroacetate Chemical compound CC(C)(C)OC(=O)OC(=O)C(F)(F)F GEXHAQTYBSQXEF-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000724195 Mycobacterium phage FRAT1 Species 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000509404 Scorpaenichthys marmoratus Species 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000007079 thiolysis reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/45—Toxoplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the 54 kDa antigen identified and described in WO 92/11366 constitutes a potentially protective agent against infection by Toxoplasma gondii. the parasite responsible for the development of toxoplasmosis in certain individuals.
- WO 92/11366 constitutes a potentially protective agent against infection by Toxoplasma gondii. the parasite responsible for the development of toxoplasmosis in certain individuals.
- TCC32 T-cell clone 32
- Tg34 54KD antigen
- the identification of the 54KD antigen represents an important advance there still exists a need to present this antigen to the immune system in a way as close as possible to the natural route.
- the present invention relates to expression systems for the 54KD antigen.
- the invention relates to the identification of the epitope on the 54KD antigen which is recognised by TCC 32 and to the synthesis of a polypeptide corresponding to this epitope.
- the invention relates to chemical conjugates or fused recombinant proteins incorporating the said epitope.
- T lymphocytes play a major role in protective immune responses to intracellular pathogens
- significant efforts have been made to identify the regions of a protein that arc recognized by the T-cell receptor.
- Approaches to design synthetic vaccines requires the appropriate selection and production of peptides which contain immunodominant T-cell epitopes.
- Several models have been elaborated to predict such antigenic segments from the primary sequence.
- the present invention provides a polypeptide corresponding to residues 197 - 216 of the 54KD antigen of T. gondii (the 'T-cell epitope').
- the invention provides a polypeptide having the amino acid sequence TDPGDVVIEELFNRIPETSV where the letters represent standard abbreviations for amino acids. This corresponds to the sequence of amino acids 197 to 216 in the 54KD antigen of T. gondii (see WO 92/11366).
- polypeptide is in purified form, preferably greater that 60% pure, more preferably over 75% pure, advantageously over 90% pure, for example
- polypeptide in substantially pure form.
- the polypeptide may be synthesised by conventional techniques, for example the Merrifield solid phase method.
- the epitope identified by the present inventors has potential for the formation of immunogenic molecules able to confer immunity to T. gondii infection.
- immunogenic molecules able to confer immunity to T. gondii infection.
- such molecules may be chemical conjugates which 'present' the epitope in the correct manner to the immune system.
- the invention provides a compound comprising the polypeptide according to the invention chemically bound to a heterologous molecule and having the ability to cause the formation of antibodies against T. gondii following internal administration to a human or animal.
- Such chemical conjugates may be formed by well known techniques, for example those described in Current Protocols in Immunology (1991; Wiley Intersciences, New York).
- a hybrid molecule incorporating the T-cell epitope described herein.
- such molecules may be expressed in particulate form so as to present the T-gondii epitope to the immune system in an effective manner.
- the invention also provides a recombinant protein comprising the polypeptide of the invention fused to a heterologous antigen, which protein is capable of forming particles on expression in a suitable host.
- the host is yeast, especially Saccharomvces cerivisae.
- the heterologous antigen is derived from
- hepatitis B surface antigen is meant the 226 amino acid S protein optionally with pre-S sequence present (for a discussion of the nature of Hepatitis B surface antigen, see Ganem, D and Varmus, H. E. (1987) Ann Rev. Biochem, 5_5_, 651 - 693).
- a recombinant protein which consists of an initiation methionine followed by the sequence TDPGDVVIEELFNRIPETSV, the 13 amino acids from the preS2 region of HBsAg and the 226 amino acids from the major HBsAg coding region (S protein).
- a vaccine composition comprising an immunologically effective amount of any compound according to the invention admixed with a pharmaceutically acceptable carrier.
- 'immunoprotective' refers to the amount necessary to elicit an immune response against a T. gondii challenge such that disease is averted or mitigated and transmission of the disease is blocked or delayed.
- Vaccine preparation is generally described in New Trends and Developments in vaccines, Voller _____] (eds), University park Press, Baltimore, Maryland, 1978.
- the amount of protein of the present invention present in each vaccine dose is selected as an amount which induces an immunoprotective response without significant adverse side effects in typical vaccines.
- each dose will comprise 1-lOOOug of protein, preferably 1 - 200ug.
- An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. Following an initial vaccination, subjects will preferably receive a boost in about 4 weeks, followed by repeated boosts every six months for as long as a risk of infection exists.
- the invention also provides a method of preventing T. gondii infection in humans or animals by administering to a human or animal in need thereof an immunologically effective amount of a vaccine composition according to the invention.
- the present inventors have surprisingly found that it is advantageous to express the 54KD antigen of T. gondii or the T-cell epitope thereof as herein described in hosts which were not mentioned in WO 92/11366.
- hosts include vaccinia virus and M. bovis - BCG. These have the advantage that they are live vaccination vehicles.
- CHO cells may also be advantageously used as host cells. These have the advantage of providing stable transformants.
- the invention provides a metiiod of producing the 54 KD antigen of T. gondii or the T-cell epitope thereof (amino acids 197 - 216) by causing the product to be expressed from a host cell comprising a vaccinia virus or M.
- bovis - BCG bovis - BCG
- the antigen produced may be engineered to be cleared of the transmembrane domain. This has the advantage of the protein being secreted into the culture supernatant.
- the full length protein or a truncated derivative may be produced in yeast. Typically removal of the transmembrane domain will involve removing the majority of residues 464 to 485.
- the invention provides a vaccinia infected cell or M. bovis -
- BCG host cell transfected or transformed with a vector comprising DNA encoding the 54KD antigen of T. gondii or the T-cell epitope thereof (amino acids 197 - 216).
- a vector comprising DNA encoding the 54KD antigen of T. gondii or the T-cell epitope thereof (amino acids 197 - 216).
- Particular vectors for this purpose also form part of the invention.
- the following examples and Figures illustrate the invention. Literature references follow the examples.
- Example 1 Identification of the Tg34 epitope recognized by the human T-cell clone 32
- the method of Berzofsky et al. (-) called the amphipathic helix model, is based on the strong correlation found between helper T-cell antigenicity and ⁇ -helical amphipathicity.
- antigenic sites are postulated to be helices with one face predominantly polar (which is recognized by the T-cell receptor) and the opposite face predominantly apolar (which is bound to class I or class II molecules of the major histocompatibility complex on the surface of the presenting cell).
- the method of Rothbard et al. ( 2 ) is based on the observation that a large percentage of helper and cytotoxic determinants contain a linear pattern composed of a charged residue or a glycine followed by two or three hydrophobic residues, and terminated by a polar residue or a glycine.
- the method of Kourilsky et al. ( 3 ), called the self peptidic model, is based on the statistically significant tendency of T immunogenic peptides to be constituted of clusters of rare tetrapeptides, as evaluated from the available sequence data banks.
- the algorithm of Berzofsky has been reproduced from the publication of Spouge et al. 0) with some adaptative changes to our computer.
- the general scheme of the program is, first, convert the amino acid sequence into a sequence of hydrophobicity values. Second, divide the hydrophobicity sequence into overlapping blocks (7 or 11 residues long). Third, in each of the blocks, search for periodicity in hydrophobicity consistent with a regular amphipathic helical structure. Fourth, distinguish between stable and unstable amphipathic helical segments. In practice, the original program offered the possibility to perform the analysis by choosing a window respectively of 7 or 11 residues.
- Tg34 protein has been submitted to this set of three programs and on the basis of the resulting analysis we have chosen to synthesize chemically three peptides out of ten predicted segments:
- the segment 197-216 contains an amphipatic ⁇ -helix predicted by both windows with amphipathic scores of 23.9 for the window of 7 residues and 28.9 for the window of 11 residues. It contains also 2 contiguous motifs of Rothbard (underlined), the first one being a pentamer and the second one a tetramer. 197 TDPGDVVIEELFNRIPETSV 216 20 amino acids
- the segment 303-410 contains two overlapping predicted amphipathic ⁇ - helices predicted by the window of 11 residues with amphipathic scores of 8.6 and 4.3). It contains also two non contiguous motifs of Rothbard (underlined), and three consecutives tetrapeptides with nul occurrence in the self peptidic human set of tetrapeptides.
- the segment 501-524 contains an amphipathic ⁇ -helix predicted by both windows with amphipathic scores of 47.4 for the window of 7 residues and 54.7 for the window of 11 residues. It contains also three motifs of Rothbard (underlined), two of them are contiguous, the first one being a pentamer and the second one a tetramer. In addition, the amino terminal part of this segment presents tetrapeptides with low occurrence values in the human subset databank.
- Peptides were synthesized by the Merrifield solid-phase method (4) Q n a fully automated peptide synthesizer (AB1 model 430 A, Foster City, CA), according to the strategy tert-butyloxycarbonyl trifluoroacetic acid (tBoc TFA).
- tBoc TFA tert-butyloxycarbonyl trifluoroacetic acid
- the tBoc-N-a protected amino-acids were coupled sequentially to a tBoc-Ala-OCH2 - phenylacetamidomethyl (Pa ) resin, a tBoc-VAl-OCH2*-Pam resin and a tBoc-tosyl- Arg-OCH2-Pam resin.
- the trifunctional amino-acids were protected as follows: Arg (tosyl), Asp and Glu (benzyl ester), Ser and Thr (benzyl ether), Lys (2-chloro- benzyloxycarbonyl), Tyr (di-chloro-benzyl), Tip (for yl), Cys (methylbenzyl), and His (dinitrophenyl).
- the protective group of His residue was removed by thiolysis before cleavage and deprotection by "low-high" hydrogen fluoride procedure.
- the crude peptides were purified by gel-filtration on TSK HW 40s (Merck, Rahway, NJ) and reverse phase HPLC on Nucleosil C ⁇ g. Then peptides were checked for homogeneity by RP-HPLC on Vydac Cjg and thin-layer chromatography, and for identity by amino-acid analysis after total acid hydrolysis.
- Peptides 197-216, 393-410 and 501-524 have been covalently linked to bovine serum albumin (BSA) respectively with dimethylsuberimidate, l-(3- dimethylaminopropyl)-3-ethylcarbodiimide and gutaraldehyde (5).
- BSA bovine serum albumin
- the conjugates were characterized to determine the ratio peptide/carrier. The quantity of protein was evaluated with the Bio-Rad Protein Assay.
- ⁇ H-labelled Boc-Leu (Dupont, NEN Research Products, Boston, MA), in order to determine the number of linked peptide by measuring the total radioactivity of the purified conjugate.
- the human T-cell clone 32 was maintained in culture by stimulation every 2-3 weeks in the presence of allogeneic irradiated PBMC, phytohaemagglutinin (PHA), and recombinant IL-2 as described (").
- PHA phytohaemagglutinin
- IL-2 recombinant IL-2 as described
- T cells were incubated with the appropriate concentration of antigen in the presence of cryopreserved cells of the autologous B lymphoblastoid cell line as antigen presenting cellsW. Proliferation was assessed three days later by [-1H]thymidine incorporation as described previously ⁇ ).
- Fig. 1 shows the dose-response curves of the T-cell clone 32 obtained with the three peptides.
- a significant proliferation was detected with the peptide corresponding to residues 197-216, with the maximum response obtained between 10 " ⁇ and 3 x 10 " ⁇ ⁇ g/ml. No response was observed with the two other peptides.
- Significant proliferation was observed in the presence of the fraction F3 or an extract of the Tg34 lysogen (positive controls); no significant proliferation was observed with the extract of the wild lambda gtl 1 lysogen (negative control).
- the conjugates were also tested in the proliferation assay; we observed a response in the presence of the conjugate corresponding to the peptide 197-216 only (data not shown).
- amino acid sequence 197-216 of the Tg34 protein contains the epitope recognized by the T-cell clone 32.
- Tg34 54 kDa antigen
- the pBluescript KS + vector carrying a ⁇ 1800 bp EcoRI DNA piece encoding the 54 kDa antigen has been described in EXAMPLE 5 of WO 92/11366. From there, a 1556 bp Nhel-Ncol DNA fragment, encompassing most of the coding sequence for the antigen, was recovered and ligated into the BgHI-NcoI sites of the multipurpose cloning vehicle pJRD184 ( Jerusalemrspreute £t al, Gene 59. 299-304, 1980) together with a 59 bp BgHI-Nhel synthetic double-stranded oligonucleotide (OL1) coding for the 5' end of the Tg34 DNA sequence (Fig.
- the resulting intermediate construct was then cut with EcoRV and Ncol to insert a second 33 bp synthetic double-stranded oligonucleotide (OL2), flanked by EcoRV (5'-end) and Ncol (3'-end), coding for the 3'-end of the Tg34 DNA sequence (Fig. 2A).
- the final construct, pNIV3404 thus carries the coding sequence for the 54 kDa antigen, including a 5' initiation consensus sequence (Kozak, M.. Cell 44. 283-292, 1986), an ATG initiation codon and a stop codon (Fig. 2B).
- pNIV3404 was then cut with BglH and EcoRV to recover a 1648 bp DNA module encoding the 54 kDa antigen which was finally cloned into the vaccinia transfer plasmid pULB5213 (a derivative of the standard vaccinia vector pSCl 1; Chakrabati s___ , Mol. Cell. Biology 5. 3404-3409, 1985).
- the resulting plasmid, pNIV3402 is illustrated in Fig. 2C; it carries the sequence for the Tg34 antigen under the control of the P7 5 vaccinia promoter.
- a MluI-BamHI fragment of 763 bp was isolated from pRIBlOOO (Thole et al.. Infection and Immunity 50. 800-806, 1985). It contains the putative promoter of the P64 (HSP60) mycobacterial antigen. It was cloned into the Hindi site of pUC19 plasmid to generate pNIV2229.
- Tg34 The complete coding sequence of Tg34 was transferred as a Bglll-EcoRV fragment of 1600 bp from pNIV3404 between the BamHI and Hindi sites of pUC19, generating pNIV3403.
- a Pstl-MscI DNA fragment was isolated from pNIV2229. It contains the P64 promoter up to the first base (G) following the translation initiation ATG. It was ligated between the EcoRI and Nhel sites of pNIV3403 with a synthetic DNA adaptor (NATBCG1/NATBCG2, Fig. 3 A) coding for the first amino acids of Tg34.
- a 1300 bp DNA containing the Kan- gene from Tn903 (Pharmacia) was then inserted into the unique PstI site of the resulting plasmid (pNIV3405) to generate pNTV3406. This construction is described in the following figure (Fig. 3B).
- Plasmid pNIV3407 results from the insertion into the unique Smal site of pNIV3406 of a 1500 bp blunted BamHI fragment derived from a temperate mycobacteriophage FRAT1 (isolated previously in our laboratory, Haeseleer, Timm and Jacobs, 1989, Acta Leprologica 7. (suppl.l) 252-253).
- the sequence coding for the Tg34 T-cell epitope (aa 196-216) was fused upstream to the DNA encoding the preS2 gene (aa 133-145) and the complete sequence for the S protein of HBV (aa 175-400) (Fig. 4A).
- Plasmid TCR50 (pRIT13220) was digested by BamHI and EcoRI to recover a 722 bp DNA fragment corresponding to amino acid residues 133-145 of the preS2 protein and 175- 400 of the S protein of HBV (Cabezon et al, Vaccines 90, 199-203, 1990).
- Synthetic oligonucleotides 64 mers were used in order to reconstitute the DNA sequence encoding the sequence for the Tg34 T-cell epitope (aa 196-216) and to provide the junction between the fragment obtained above and the plasmid FF6 (pRIT13717) cut by Ncol and EcoRI.
- the pRIT13717 vector contains a yeast glyceraldehyde-3P- dehydrogenase (TDH3) promoter fragment followed by a yeast DNA fragment carrying the ARG3 transcription terminator (Fig. 4B).
- TDH3 yeast glyceraldehyde-3P- dehydrogenase
- Fig. 4B yeast DNA fragment carrying the ARG3 transcription terminator
- the 2980 bp expression cassette was excised as a BgUI-Sall fragment and inserted into the yeast shuttle vector OJ10 (pRIT12741) to obtain pNIV3409 (Fig. 4C).
- the pRIT12741 vector is composed of the yeast 2-micron DNA and the yeast LEU2 as marker of selection in yeast (Harford et al, Postgrad. Med. J. 63, 65-70, 1987).
- the cassette inserted in pNIV3409 is predicted to express a 260 amino acids protein.
- the hybrid protein consists of an initiation methionine followed by the 20 amino acids of the Tg34 T-cell epitope, the 13 amino acids from the preS2 region and the 226 amino acids from the major HBsAg coding region.
- pNIV 3412 contains, under the control of the major immediate early promoter of the human cytomegalovirus (hCMV - MIE), the sequence encoding the 54KDa antigen described in Example 2 A.
- the amino acid sequence of the 54KDa antigen contains a putative membrane - anchorage domain spanning residues 464 to 485, which may prevent secretion of the recombinant protein by host cells.
- This construct was then digested with Sma I to accomodate, by ligation, into this site, a 151 bp Hpa I - EcoRI DNA fragment obtained by the polymerase chain reaction (primers 1 and 2, DNA of pNIV 3402 as template, Fig 6b).
- the final construct, pNIV 3414 thus encodes, under the control of the hCMV promoter, a truncated form of the 54 KDa antigen lacking residues 464 to 485 (Fig. 6c).
- the recombinant transfer plasmid pNIV3402 was transfected into vaccinia- infected CV-1 cells and recombinant viruses were isolated after Bromo-uridine selection and plaque purification on the basis of their blue colour in the presence of X-gal. They will be referred to as VV3402.
- the human HI 43 fibroblast TK strain was used preferably for plaque assays.
- the vaccinia virus used to infect cells was of the WR type (origin Borysiewicz, U.K.). The procedure follows that one previously described for the obtention of vaccinia virus recombinants (Mackett M. and Smith G.L., J.Gen. Virology 67. 2067-2082, 1986; Mackett M., Smith G.L., and Moss B., J. Virology 49. 857-864, 1984).
- the recombinant vaccinia virus V V3402 was used to infect CV- 1 cells in culture at a multiplicity of infection of 1. Infected cells (about 3.10*-' per assay) and spent culture medium (about 2 ml) were collected between 18 and 48 hours post infection. The presence of the 54 kDa antigen was identified following separation of proteins by polyacrylamide gel electrophoresis in the presence of 12% sodium dodecyl sulphate, transfer onto nitrocellulose membranes and immunodetection. Details of these procedures are given in WO 92/11366.
- Plasmids pNIV3406 and pNIV3407 were electroporated into M.bovis-BCG: the first plasmid was used in its linear form (via Seal digestion) and the second one was used as a circular molecule. M.bovis-BCG recombinants recovered from die transformation procedure were analysed for expression by the immunodetection methods described under subtitles A 13 and A 15 of WO 92/11366.
- Plasmid pNIV3409 was used to transform S.cerevisiae strain DC5 (his3- 11 , his3-15, leu2-3, leu2-112, canl-11 cir° , Harford and Peeters, Curr.Genet. 11:315- 319, 1987) to the Leu + phenotype.
- the transformants were named Y420. One of them was grown in 40ml of yeast nitrogen base minimal medium with 2% glucose as carbon source up to mid exponential phase.
- yeast strain Y420 expresses a fusion protein of MW 28 kDa that consists of an initiation methionine followed by the 20 amino acids of die Tg34 T-cell epitope, the amino acids 133-145 from the preS2 region and the 226 amino acids from the major HBsAg coding region.
- Strain Y420 was grown in selective medium (800ml + 80 ⁇ g/ml histidine) to late log phase. Cells were collected by centrifugation, washed with cold PBS and resuspended in 5ml of 50mM sodium phosphate buffer (pH 8.1), 4mM EDTA (ethylenediaminetetraacetic and disodium salt), 1% Tween-20 (polyoxyethylene sorbitan monolaurate), 4mM PMSF (phenylmethylsulfonylfluoride) and 10% isopropanol. Cells were disrupted by passage twice through a French pressure cell at 20,000 psi. The suspension was centrifuged for 30 min at 30,000 xg.
- selective medium 800ml + 80 ⁇ g/ml histidine
- the total protein cencentration of the supernatant liquid was measured by the Bio-Rad protein assay (n° 500-0001) based on the Bradford dye-binding procedure (Bradford, M. (1976) Anal. Biochem. 72, 248).
- the presence of HBsAg was assayed using an ELISA kit (Enzygnost-HBsAg micro) commercially available from Behringwerke, Marburg, Germany).
- Plasmid.pNI V3417 , ⁇ NIV3421 and pNIV3423 were used to transform S. cerevisiae strain DC5 to the Leu + phenotype.
- the transformants were named respectively YN479, YN478 and YN481. Cultures and analysis of crude extracts were released as described above. Proteins in the culture medium was precipitated by
- TCA trichloroacetic acid
- Plasmid pNIV 3412 was transfected by calcium phosphate coprecipitation into the CHO - Kl cells, using 20 ug DNA per 1.25 10 6 cells.
- the CHO - Kl cells were grown in GMEM - S medium (Gibco).
- Transfectants were selected by addition of 25 uM methionine sulfoximine two days after transfection. After 10 to 14 days, resistant colonies were picked up, transferred into 96 well plates, and later into 24 well plates and subsequently to 80 cm ⁇ flasks. GS transfectants were assayed for die 54KDa antigen when cells reached about 80% confluency. The procedure follows the one described in Cockett & al, Bio/Technology 8, 662 - 667 (1990).
- a 1648 bp Hind III-Bgi ⁇ DNA fragment was recovered from pNIV3402 and introduced blund-ended in the correct orientation for expression into the blunt ended BamHI site of the expression vector ⁇ RTT13145 (TCM97) (FIG.7).
- the resulting plasmid pNIV3417 contains, under die control of the ARG3 promoter, the sequence encoding the 54KD antigen described in example 2A.
- yeast secretion from the yeast S.cerevisiae of heterologous proteins with their own signal sequence has observed in some but not all cases. However, their secretion has mostly achieved by fusing signal sequences of yeast secretory proteins to the coding region of the foreign protein (see Romanos et al (1992) Yeast 8: 423-488). The signal sequence for the yeast pheromone MF ⁇ -1 has proved particularly productive in this respect (see Brake) (1989) in Yeast Genetic Engineering 269-280).
- Plasmid pNIV3402 was digested by Rsal and Sail to recover a 470 bp DNA fragment.
- Synthetic oligonucleotides (65 mers) were used in order to reconstitute the DNA sequence encoding the signal sequence of MF ⁇ -1 (19 amino acids) and to provide the juction between the fragment obtained above and die plasmid pUC19 cut by Hind Hl-Sall (FIG. ⁇ a).
- the resulting intermediate construct was then cut the Sail and BamHI to insert a Sall-BglH DNA fragment from pNIV3402 to give the pNIV3416 (FIG.8b). This one was cut by Hind III and EC ⁇ RI to recover a 1626 bp DNA fragment, blunt-ended and introduced in the blunt-ended
- pNIV3421 BamHI site of the pRIT 13145 (TCM97).
- the final construct, pNIV3421 thus encodes, under the control of the ARG3 promoter, the signal sequence of MF ⁇ -1 fused to residues 28 to 538 of the 54KD antigen (FIG. 8c).
- the resulting expression plasmid, pNIV3423 contains, under the control of the ARG3 promoter, the sequence encoding the signal sequence of MF ⁇ -1 followed by residues 28 to 465 and 486 to 538 of the 54KD antigen (FIG.9b).
- T-immunogenic peptides are constituted of rare sequence patterns. Use in the identification of T epitopes in die human imunodeficiency virus gag protein. Eur. J. Immunol., 18, pp 1547-1553.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides a polypeptide corresponding to residues 197 - 216 of the 54 KDa antigen of T. gondii, having the amino acid sequence TDPGDVVIEELFNRIPETSV. Also within the scope of the invention is a method of producing the 54 KD antigen of T. gondii or the polypeptide corresponding to residues 197 - 216 thereof by expression from a host cell, for example from a host cell comprising a vaccinia virus or from a CHO cell.
Description
CLONING, EXPRESSION AND VACCINE COMPOSITION CORRESPONDING TO A PEPTIDE
ANTIGEN OF TOXOPLASMA GONDII
The 54 kDa antigen identified and described in WO 92/11366 constitutes a potentially protective agent against infection by Toxoplasma gondii. the parasite responsible for the development of toxoplasmosis in certain individuals. In WO
92/11366 human T-cell clones specific for T. gondii were obtained, one of which, designated T-cell clone 32 (TCC32), was used to identify the 54KD antigen (also known as Tg34).
Whilst the identification of the 54KD antigen represents an important advance there still exists a need to present this antigen to the immune system in a way as close as possible to the natural route. In one aspect he present invention relates to expression systems for the 54KD antigen. In another aspect the invention relates to the identification of the epitope on the 54KD antigen which is recognised by TCC 32 and to the synthesis of a polypeptide corresponding to this epitope. In another aspect the invention relates to chemical conjugates or fused recombinant proteins incorporating the said epitope.
Because T lymphocytes play a major role in protective immune responses to intracellular pathogens, significant efforts have been made to identify the regions of a protein that arc recognized by the T-cell receptor. Approaches to design synthetic vaccines requires the appropriate selection and production of peptides which contain immunodominant T-cell epitopes. Several models have been elaborated to predict such antigenic segments from the primary sequence.
In making the present invention, we applied three predictive models in order to determine the region of the cloned Tg34 protein of Toxoplasma gondiiC7) which contains the epitope recognized by the human T-cell clone 32. The details are given hereinbelow (see Example 1) from which it was found that the said epitope corresponded to amino acids 197 to 216 of the 54KD antigen of T. gondii described in WO 92/11366.
Accordingly in a first aspect the present invention provides a polypeptide corresponding to residues 197 - 216 of the 54KD antigen of T. gondii (the 'T-cell epitope').
In a related aspect the invention provides a polypeptide having the amino acid sequence TDPGDVVIEELFNRIPETSV where the letters represent standard abbreviations for amino acids. This corresponds to the sequence of amino acids 197 to 216 in the 54KD antigen of T. gondii (see WO 92/11366).
Preferably the polypeptide is in purified form, preferably greater that 60% pure, more preferably over 75% pure, advantageously over 90% pure, for example
95-100% pure.
In a preferred aspect the polypeptide (T-cell epitope) is in substantially pure
form.
The polypeptide may be synthesised by conventional techniques, for example the Merrifield solid phase method.
The epitope identified by the present inventors has potential for the formation of immunogenic molecules able to confer immunity to T. gondii infection. In one aspect such molecules may be chemical conjugates which 'present' the epitope in the correct manner to the immune system.
Accordingly in a further aspect the invention provides a compound comprising the polypeptide according to the invention chemically bound to a heterologous molecule and having the ability to cause the formation of antibodies against T. gondii following internal administration to a human or animal.
Such chemical conjugates may be formed by well known techniques, for example those described in Current Protocols in Immunology (1991; Wiley Intersciences, New York). In another aspect it is possible to form, by recombinant DNA techniques,a hybrid molecule incorporating the T-cell epitope described herein. Using techniques analogous to those already described in the literature (see Martineau et al (1991) Bio/Technology 9_, 170 - 179; Rutgers et al (1988) Bio/Technology, t_, 1065 - 1070), such molecules may be expressed in particulate form so as to present the T-gondii epitope to the immune system in an effective manner.
Accordingly the invention also provides a recombinant protein comprising the polypeptide of the invention fused to a heterologous antigen, which protein is capable of forming particles on expression in a suitable host.
Preferably the host is yeast, especially Saccharomvces cerivisae. In a particularly preferred aspect the heterologous antigen is derived from
Hepatitis B surface antigen.
By hepatitis B surface antigen is meant the 226 amino acid S protein optionally with pre-S sequence present (for a discussion of the nature of Hepatitis B surface antigen, see Ganem, D and Varmus, H. E. (1987) Ann Rev. Biochem, 5_5_, 651 - 693).
In a particular embodiment of the invention there is provided a recombinant protein which consists of an initiation methionine followed by the sequence TDPGDVVIEELFNRIPETSV, the 13 amino acids from the preS2 region of HBsAg and the 226 amino acids from the major HBsAg coding region (S protein). There is also provided a vaccine composition comprising an immunologically effective amount of any compound according to the invention admixed with a pharmaceutically acceptable carrier.
The term 'immunoprotective' refers to the amount necessary to elicit an immune response against a T. gondii challenge such that disease is averted or
mitigated and transmission of the disease is blocked or delayed.
Vaccine preparation is generally described in New Trends and Developments in vaccines, Voller _____] (eds), University park Press, Baltimore, Maryland, 1978.
The amount of protein of the present invention present in each vaccine dose is selected as an amount which induces an immunoprotective response without significant adverse side effects in typical vaccines.
Such amount will vary depending on which specific immunogen is employed and whether or not the vaccine is adjuvanted. Generally it is expected that each dose will comprise 1-lOOOug of protein, preferably 1 - 200ug. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. Following an initial vaccination, subjects will preferably receive a boost in about 4 weeks, followed by repeated boosts every six months for as long as a risk of infection exists.
The invention also provides a method of preventing T. gondii infection in humans or animals by administering to a human or animal in need thereof an immunologically effective amount of a vaccine composition according to the invention.
As described further in the examples below the present inventors have surprisingly found that it is advantageous to express the 54KD antigen of T. gondii or the T-cell epitope thereof as herein described in hosts which were not mentioned in WO 92/11366. Particular hosts include vaccinia virus and M. bovis - BCG. These have the advantage that they are live vaccination vehicles. CHO cells may also be advantageously used as host cells. These have the advantage of providing stable transformants. Accordingly in yet a further aspect the invention provides a metiiod of producing the 54 KD antigen of T. gondii or the T-cell epitope thereof (amino acids 197 - 216) by causing the product to be expressed from a host cell comprising a vaccinia virus or M. bovis - BCG, followed by purification of the product by conventional techniques. The antigen produced may be engineered to be cleared of the transmembrane domain. This has the advantage of the protein being secreted into the culture supernatant. The full length protein or a truncated derivative may be produced in yeast. Typically removal of the transmembrane domain will involve removing the majority of residues 464 to 485. In a related aspect the invention provides a vaccinia infected cell or M. bovis -
BCG host cell transfected or transformed with a vector comprising DNA encoding the 54KD antigen of T. gondii or the T-cell epitope thereof (amino acids 197 - 216). Particular vectors for this purpose,described below, also form part of the invention. The following examples and Figures (explained below) illustrate the
invention. Literature references follow the examples.
Example 1: Identification of the Tg34 epitope recognized by the human T-cell clone 32 The method of Berzofsky et al. (-), called the amphipathic helix model, is based on the strong correlation found between helper T-cell antigenicity and α-helical amphipathicity. In this model, antigenic sites are postulated to be helices with one face predominantly polar (which is recognized by the T-cell receptor) and the opposite face predominantly apolar (which is bound to class I or class II molecules of the major histocompatibility complex on the surface of the presenting cell).
The method of Rothbard et al. (2) is based on the observation that a large percentage of helper and cytotoxic determinants contain a linear pattern composed of a charged residue or a glycine followed by two or three hydrophobic residues, and terminated by a polar residue or a glycine. The method of Kourilsky et al. (3), called the self peptidic model, is based on the statistically significant tendency of T immunogenic peptides to be constituted of clusters of rare tetrapeptides, as evaluated from the available sequence data banks.
Methods and Results 1. Prediction of T cell epitopes
The algorithm of Berzofsky has been reproduced from the publication of Spouge et al. 0) with some adaptative changes to our computer. The general scheme of the program is, first, convert the amino acid sequence into a sequence of hydrophobicity values. Second, divide the hydrophobicity sequence into overlapping blocks (7 or 11 residues long). Third, in each of the blocks, search for periodicity in hydrophobicity consistent with a regular amphipathic helical structure. Fourth, distinguish between stable and unstable amphipathic helical segments. In practice, the original program offered the possibility to perform the analysis by choosing a window respectively of 7 or 11 residues. We have added the possibility to use both windows consecutively and to represent the amphipathic segments aligned under the primary sequence by using different symbols in order to distinguish regions predicted by both windows, from regions predicted by only one window and from regions predicted by the window of 11 residues but with a weak amphipathic score (<8).
The algorithm of Rothbard has been deduced from the publication mentioned above (2) where the four sets of amino acids composing the proposed patterns are defined. We have just added tyrosine to the fourth set containing polar residues because we observed, in the table reporting the known epitopes containing the motifs, that Tyr could be present in the last position of a motif of either 4 or 5 residues.
To implement the algorithm of Kourilsky, we first generated a subset of the
protein sequence databank SWISSPROT containing only human sequences from which all immune system-related polymorphic protein sequences were excluded (i.e. immunoglobulins, T-cell receptors, MHC molecules). In a second step, this databank subset, representing the somatic self catalog of the human specie, was read dirough a window of 4 residues and the number of occurrence for all the possible tetrapeptide sequences were scored using a four dimensional matrix. Finally, submission of a proteic sequence to this program gives for each tetrapeptide found in this sequence the corresponding value reported by the matrix.
However, because different regions of a given protein may be selected by each model, we have written a program which performs under the primary sequence of interest an alignment of the results generated from each predictive method. This approach has been used to increase the likelihood of identification of T-cell determinants allowing to focus upon those antigenic segments that are congruently predicted by different algorithms. All the computer programs described above have been written in FORTRAN, a powerful scientific programming language.
The primary sequence of Tg34 protein has been submitted to this set of three programs and on the basis of the resulting analysis we have chosen to synthesize chemically three peptides out of ten predicted segments:
The segment 197-216 contains an amphipatic α-helix predicted by both windows with amphipathic scores of 23.9 for the window of 7 residues and 28.9 for the window of 11 residues. It contains also 2 contiguous motifs of Rothbard (underlined), the first one being a pentamer and the second one a tetramer. 197 TDPGDVVIEELFNRIPETSV 216 20 amino acids
The segment 303-410 contains two overlapping predicted amphipathic α- helices predicted by the window of 11 residues with amphipathic scores of 8.6 and 4.3). It contains also two non contiguous motifs of Rothbard (underlined), and three consecutives tetrapeptides with nul occurrence in the self peptidic human set of tetrapeptides.
393 LQLIRLΔΔSLQHYGLVHA 410 18 amino acids The segment 501-524 contains an amphipathic α-helix predicted by both windows with amphipathic scores of 47.4 for the window of 7 residues and 54.7 for the window of 11 residues. It contains also three motifs of Rothbard (underlined), two of them are contiguous, the first one being a pentamer and the second one a tetramer. In addition, the amino terminal part of this segment presents tetrapeptides with low occurrence values in the human subset databank.
501 IEWIYRRCKNIPOPVRALLEGFLR 524 24 amino acids
2. Synthesis of Peptides and Conjugates
Peptides were synthesized by the Merrifield solid-phase method (4) Qn a fully automated peptide synthesizer (AB1 model 430 A, Foster City, CA), according to the strategy tert-butyloxycarbonyl trifluoroacetic acid (tBoc TFA). The tBoc-N-a protected amino-acids were coupled sequentially to a tBoc-Ala-OCH2 - phenylacetamidomethyl (Pa ) resin, a tBoc-VAl-OCH2*-Pam resin and a tBoc-tosyl- Arg-OCH2-Pam resin. The trifunctional amino-acids were protected as follows: Arg (tosyl), Asp and Glu (benzyl ester), Ser and Thr (benzyl ether), Lys (2-chloro- benzyloxycarbonyl), Tyr (di-chloro-benzyl), Tip (for yl), Cys (methylbenzyl), and His (dinitrophenyl). At the end of the synthesis, the protective group of His residue was removed by thiolysis before cleavage and deprotection by "low-high" hydrogen fluoride procedure. The crude peptides were purified by gel-filtration on TSK HW 40s (Merck, Rahway, NJ) and reverse phase HPLC on Nucleosil C\ g. Then peptides were checked for homogeneity by RP-HPLC on Vydac Cjg and thin-layer chromatography, and for identity by amino-acid analysis after total acid hydrolysis.
Peptides 197-216, 393-410 and 501-524 have been covalently linked to bovine serum albumin (BSA) respectively with dimethylsuberimidate, l-(3- dimethylaminopropyl)-3-ethylcarbodiimide and gutaraldehyde (5). After dialysis to remove any uncoupled peptide, the conjugates were characterized to determine the ratio peptide/carrier. The quantity of protein was evaluated with the Bio-Rad Protein Assay. During peptide synthesis, we used ^H-labelled Boc-Leu (Dupont, NEN Research Products, Boston, MA), in order to determine the number of linked peptide by measuring the total radioactivity of the purified conjugate.
3. T Cell Proliferation Assay
The human T-cell clone 32 was maintained in culture by stimulation every 2-3 weeks in the presence of allogeneic irradiated PBMC, phytohaemagglutinin (PHA), and recombinant IL-2 as described ("). For proliferation assays, T cells were incubated with the appropriate concentration of antigen in the presence of cryopreserved cells of the autologous B lymphoblastoid cell line as antigen presenting cellsW. Proliferation was assessed three days later by [-1H]thymidine incorporation as described previously^).
Fig. 1 shows the dose-response curves of the T-cell clone 32 obtained with the three peptides. As can be observed a significant proliferation was detected with the peptide corresponding to residues 197-216, with the maximum response obtained between 10"^ and 3 x 10"^ μg/ml. No response was observed with the two other peptides. Significant proliferation was observed in the presence of the fraction F3 or an extract of the Tg34 lysogen (positive controls); no significant proliferation was observed with the extract of the wild lambda gtl 1 lysogen (negative control). The
conjugates were also tested in the proliferation assay; we observed a response in the presence of the conjugate corresponding to the peptide 197-216 only (data not shown).
It can be concluded that the amino acid sequence 197-216 of the Tg34 protein contains the epitope recognized by the T-cell clone 32.
EXAMPLE 2
Construction of recombinant vectors carrying the 54 kDa antigen (Tg34), either complete or restricted to the T-cell epitope (aa 197-216).
A. Vector Construction for Transfer into Vaccinia Virus
The pBluescript KS+ vector carrying a ± 1800 bp EcoRI DNA piece encoding the 54 kDa antigen (pNIV3401) has been described in EXAMPLE 5 of WO 92/11366. From there, a 1556 bp Nhel-Ncol DNA fragment, encompassing most of the coding sequence for the antigen, was recovered and ligated into the BgHI-NcoI sites of the multipurpose cloning vehicle pJRD184 (Heuterspreute £t al, Gene 59. 299-304, 1980) together with a 59 bp BgHI-Nhel synthetic double-stranded oligonucleotide (OL1) coding for the 5' end of the Tg34 DNA sequence (Fig. 2A). The resulting intermediate construct was then cut with EcoRV and Ncol to insert a second 33 bp synthetic double-stranded oligonucleotide (OL2), flanked by EcoRV (5'-end) and Ncol (3'-end), coding for the 3'-end of the Tg34 DNA sequence (Fig. 2A). The final construct, pNIV3404, thus carries the coding sequence for the 54 kDa antigen, including a 5' initiation consensus sequence (Kozak, M.. Cell 44. 283-292, 1986), an ATG initiation codon and a stop codon (Fig. 2B). pNIV3404 was then cut with BglH and EcoRV to recover a 1648 bp DNA module encoding the 54 kDa antigen which was finally cloned into the vaccinia transfer plasmid pULB5213 (a derivative of the standard vaccinia vector pSCl 1; Chakrabati s___ , Mol. Cell. Biology 5. 3404-3409, 1985). The resulting plasmid, pNIV3402, is illustrated in Fig. 2C; it carries the sequence for the Tg34 antigen under the control of the P7 5 vaccinia promoter.
B. Construction of transfer plasmids for expression into Mycobacterium bovis-BCG
1. Preparation of starting materials
a) Plasmid pNIV2229
A MluI-BamHI fragment of 763 bp was isolated from pRIBlOOO (Thole et al..
Infection and Immunity 50. 800-806, 1985). It contains the putative promoter of the P64 (HSP60) mycobacterial antigen. It was cloned into the Hindi site of pUC19 plasmid to generate pNIV2229.
b) Plasmid pNIV3403
The complete coding sequence of Tg34 was transferred as a Bglll-EcoRV fragment of 1600 bp from pNIV3404 between the BamHI and Hindi sites of pUC19, generating pNIV3403.
2. Construction of pNIV3406
A Pstl-MscI DNA fragment was isolated from pNIV2229. It contains the P64 promoter up to the first base (G) following the translation initiation ATG. It was ligated between the EcoRI and Nhel sites of pNIV3403 with a synthetic DNA adaptor (NATBCG1/NATBCG2, Fig. 3 A) coding for the first amino acids of Tg34. A 1300 bp DNA containing the Kan- gene from Tn903 (Pharmacia) was then inserted into the unique PstI site of the resulting plasmid (pNIV3405) to generate pNTV3406. This construction is described in the following figure (Fig. 3B).
3. Construction of pNIV3407 Plasmid pNIV3407 results from the insertion into the unique Smal site of pNIV3406 of a 1500 bp blunted BamHI fragment derived from a temperate mycobacteriophage FRAT1 (isolated previously in our laboratory, Haeseleer, Timm and Jacobs, 1989, Acta Leprologica 7. (suppl.l) 252-253).
C. Vector construction for expression in yeast as particles made of a fusion between the Tg34 T-cell epitope (aa 197-216) and the preS2-S antigen of the hepatitis B virus (HBV)
In order to use HBsAg particles as carriers for the presentation of the Tg34 T- cell epitope to the immune system, the sequence coding for the Tg34 T-cell epitope (aa 196-216) was fused upstream to the DNA encoding the preS2 gene (aa 133-145) and the complete sequence for the S protein of HBV (aa 175-400) (Fig. 4A). Plasmid TCR50 (pRIT13220) was digested by BamHI and EcoRI to recover a 722 bp DNA fragment corresponding to amino acid residues 133-145 of the preS2 protein and 175- 400 of the S protein of HBV (Cabezon et al, Vaccines 90, 199-203, 1990). Synthetic oligonucleotides (64 mers) were used in order to reconstitute the DNA sequence encoding the sequence for the Tg34 T-cell epitope (aa 196-216) and to provide the junction between the fragment obtained above and the plasmid FF6 (pRIT13717) cut by Ncol and EcoRI. The pRIT13717 vector contains a yeast glyceraldehyde-3P- dehydrogenase (TDH3) promoter fragment followed by a yeast DNA fragment
carrying the ARG3 transcription terminator (Fig. 4B). The 2980 bp expression cassette was excised as a BgUI-Sall fragment and inserted into the yeast shuttle vector OJ10 (pRIT12741) to obtain pNIV3409 (Fig. 4C). The pRIT12741 vector is composed of the yeast 2-micron DNA and the yeast LEU2 as marker of selection in yeast (Harford et al, Postgrad. Med. J. 63, 65-70, 1987). The cassette inserted in pNIV3409 is predicted to express a 260 amino acids protein. The hybrid protein consists of an initiation methionine followed by the 20 amino acids of the Tg34 T-cell epitope, the 13 amino acids from the preS2 region and the 226 amino acids from the major HBsAg coding region.
D. Vector construction for expression in CHO cells
a) The 54 KDa antigen
Starting from the plasmid pNIV 3404 (see Example 2A), a 1648 bp Hind III - EcoRV DNA fragment was recovered by digestion and inserted into the pRIT 14073 eukaryotic expression vector derived from pEE 14 (Cockett et al, 1990, Bio/Technology, 8, 662 - 667), cut with Hind III and Sma I. The resulting expression plasmid, pNIV 3412 (Fig. 5) contains, under the control of the major immediate early promoter of the human cytomegalovirus (hCMV - MIE), the sequence encoding the 54KDa antigen described in Example 2 A.
b) The truncated 54 KDa antigen
The amino acid sequence of the 54KDa antigen contains a putative membrane - anchorage domain spanning residues 464 to 485, which may prevent secretion of the recombinant protein by host cells. We have constructed a DNA encoding a truncated form of the 54 KDa antigen wherein the sequence corresponding to residues 464 to 485 has been deleted. The construction proceeded as follows. A 1356 bp Hind III - _____ I DNA fragment was recovered from plasmid pNIV 3402 (see Example 2A) and introduced, together with a 49 bp ≤fς I - Sma I synthetic DNA fragment (Fig. 6a), into the pRIT 14073 expression vector cut with Hind III and Sma I, yielding an intermediate construct. This construct was then digested with Sma I to accomodate, by ligation, into this site, a 151 bp Hpa I - EcoRI DNA fragment obtained by the polymerase chain reaction (primers 1 and 2, DNA of pNIV 3402 as template, Fig 6b). The final construct, pNIV 3414, thus encodes, under the control of the hCMV promoter, a truncated form of the 54 KDa antigen lacking residues 464 to 485 (Fig. 6c).
EXAMPLE 3
Expression of the 54 kDa antigen, complete or restricted to the T-cell epitope (aa
197-216), in host cells
A. Expression in eukaryotic cells via vaccinia virus recombinants
The recombinant transfer plasmid pNIV3402 was transfected into vaccinia- infected CV-1 cells and recombinant viruses were isolated after Bromo-uridine selection and plaque purification on the basis of their blue colour in the presence of X-gal. They will be referred to as VV3402. The human HI 43 fibroblast TK strain was used preferably for plaque assays. The vaccinia virus used to infect cells was of the WR type (origin Borysiewicz, U.K.). The procedure follows that one previously described for the obtention of vaccinia virus recombinants (Mackett M. and Smith G.L., J.Gen. Virology 67. 2067-2082, 1986; Mackett M., Smith G.L., and Moss B., J. Virology 49. 857-864, 1984).
The recombinant vaccinia virus V V3402 was used to infect CV- 1 cells in culture at a multiplicity of infection of 1. Infected cells (about 3.10*-' per assay) and spent culture medium (about 2 ml) were collected between 18 and 48 hours post infection. The presence of the 54 kDa antigen was identified following separation of proteins by polyacrylamide gel electrophoresis in the presence of 12% sodium dodecyl sulphate, transfer onto nitrocellulose membranes and immunodetection. Details of these procedures are given in WO 92/11366.
B. Expression in M.bovis-BCG
Plasmids pNIV3406 and pNIV3407 were electroporated into M.bovis-BCG: the first plasmid was used in its linear form (via Seal digestion) and the second one was used as a circular molecule. M.bovis-BCG recombinants recovered from die transformation procedure were analysed for expression by the immunodetection methods described under subtitles A 13 and A 15 of WO 92/11366.
C. Expression in Yeast
1. Plasmid pNIV3409 was used to transform S.cerevisiae strain DC5 (his3- 11 , his3-15, leu2-3, leu2-112, canl-11 cir° , Harford and Peeters, Curr.Genet. 11:315- 319, 1987) to the Leu+ phenotype. The transformants were named Y420. One of them was grown in 40ml of yeast nitrogen base minimal medium with 2% glucose as carbon source up to mid exponential phase. Cells were washed, collected by centrifugation and broken with glass beads in 300ml of Tris-HCl 25mM pH 8, 4 mM EDTA, 1% Tween 20, 4mM phenylmethylsulfonyl fluoride, 10% propanol-2. The homogenates were centrifuged at 30,000 x g for 30 min to obtain crude extracts. The supernatant (± 50μg of total protein) was analyzed on 12.5% SDS-polyacrylamide gel. Separated protein were then blotted on nitrocellulose (Towbin et al., Proc. Natl. Acad. Sci. USA 76:4350-4354, 1979) and the sheet was incubated with monoclonal antibodies directed against the HBsAg (mAb HBS1, SmithKline Beecham) or the
preS2 region (mAb S2.5, SmithKline Beecham). Detection of die primary antibody was by the alkaline phosphatase method. The anti-IgG second antibodies conjugated with alkaline phosphatase were detected by NBT (nitroblue tetrazolium) and BCIP (5- bromo-4-chloro-3-indolyl phosphate). A protein of about 28 kDa not present in the negative control (Y1017) was revealed with the mAb's HBS 1 and S2.5. These results indicate that the yeast strain Y420 expresses a fusion protein of MW 28 kDa that consists of an initiation methionine followed by the 20 amino acids of die Tg34 T-cell epitope, the amino acids 133-145 from the preS2 region and the 226 amino acids from the major HBsAg coding region.
2) Formation of particles
Strain Y420 was grown in selective medium (800ml + 80μg/ml histidine) to late log phase. Cells were collected by centrifugation, washed with cold PBS and resuspended in 5ml of 50mM sodium phosphate buffer (pH 8.1), 4mM EDTA (ethylenediaminetetraacetic and disodium salt), 1% Tween-20 (polyoxyethylene sorbitan monolaurate), 4mM PMSF (phenylmethylsulfonylfluoride) and 10% isopropanol. Cells were disrupted by passage twice through a French pressure cell at 20,000 psi. The suspension was centrifuged for 30 min at 30,000 xg. The total protein cencentration of the supernatant liquid was measured by the Bio-Rad protein assay (n° 500-0001) based on the Bradford dye-binding procedure (Bradford, M. (1976) Anal. Biochem. 72, 248). The presence of HBsAg was assayed using an ELISA kit (Enzygnost-HBsAg micro) commercially available from Behringwerke, Marburg, Germany).
7ml of crude cells extracts were centrifuged to equilibrium in 1.5M CsCl, 25mM sodium phosphate buffer, pH 7.4, for 68 hours at 40,000 xg in a Beckman 60 Ti rotor. Collected fractions were assayed for the presence of HBsAg with the ELISA method described above. HBsAg was found to equilibrate to 1.22 g/cm3. Immunoblot analysis of the gradient fraction confirmed the ELISA results (Fig.7A). 0.5ml of the material from the CsCl peak fraction dialysed against PBS was subjected to a velocity sucrose gradient for 13 hours at 38,OOOg in a SW40 rotor.
Each fraction was analyzed for HBsAg antigenicity and for the presence of the hybrid protein respectively by ELISA (Enzygnost-HBsAg micro) and by immunoblot with the mAb HBS1 (Fig.7B). The results show that the hybrid protein assembles into lipoproteic particles.
C. Expression in yeast
3) Plasmid.pNI V3417 , ρNIV3421 and pNIV3423 were used to transform S. cerevisiae strain DC5 to the Leu+ phenotype. The transformants were named
respectively YN479, YN478 and YN481. Cultures and analysis of crude extracts were released as described above. Proteins in the culture medium was precipitated by
TCA (trichloroacetic acid).
D. Expression in CHO cells (stable transformants)
a) The 54 KDa antigen
Plasmid pNIV 3412 was transfected by calcium phosphate coprecipitation into the CHO - Kl cells, using 20 ug DNA per 1.25 106 cells. The CHO - Kl cells were grown in GMEM - S medium (Gibco). Transfectants were selected by addition of 25 uM methionine sulfoximine two days after transfection. After 10 to 14 days, resistant colonies were picked up, transferred into 96 well plates, and later into 24 well plates and subsequently to 80 cm^ flasks. GS transfectants were assayed for die 54KDa antigen when cells reached about 80% confluency. The procedure follows the one described in Cockett & al, Bio/Technology 8, 662 - 667 (1990).
b) The truncated 54 KDa antigen
Procedures for the expression of the truncated 54 KDa antigen followed tiiose described above.
E. Vector construction for expression of the 54KD antigen in yeast
A 1648 bp Hind III-Bgiπ DNA fragment was recovered from pNIV3402 and introduced blund-ended in the correct orientation for expression into the blunt ended BamHI site of the expression vector ρRTT13145 (TCM97) (FIG.7). The resulting plasmid pNIV3417, contains, under die control of the ARG3 promoter, the sequence encoding the 54KD antigen described in example 2A.
Secretion from the yeast S.cerevisiae of heterologous proteins with their own signal sequence has observed in some but not all cases. However, their secretion has mostly achieved by fusing signal sequences of yeast secretory proteins to the coding region of the foreign protein (see Romanos et al (1992) Yeast 8: 423-488). The signal sequence for the yeast pheromone MFα-1 has proved particularly productive in this respect (see Brake) (1989) in Yeast Genetic Engineering 269-280).
Thus, we have constructed a DNA encoding for the signal sequence of MFα-1 followed by die amino acid residues 28 to 538 of Tg54 protein. The construction proceeded as follows. Plasmid pNIV3402 was digested by Rsal and Sail to recover a 470 bp DNA fragment. Synthetic oligonucleotides (65 mers) were used in order to reconstitute the DNA sequence encoding the signal sequence of MFα-1 (19 amino acids) and to provide the juction between the fragment obtained above and die plasmid pUC19 cut by Hind Hl-Sall (FIG.δa). The resulting intermediate construct
was then cut the Sail and BamHI to insert a Sall-BglH DNA fragment from pNIV3402 to give the pNIV3416 (FIG.8b). This one was cut by Hind III and ECΩRI to recover a 1626 bp DNA fragment, blunt-ended and introduced in the blunt-ended
BamHI site of the pRIT 13145 (TCM97). The final construct, pNIV3421, thus encodes, under the control of the ARG3 promoter, the signal sequence of MFα-1 fused to residues 28 to 538 of the 54KD antigen (FIG. 8c).
As die putative membrane-anchorage domain of the 54KD antigen (residues
464 to 485) may prevent secretion of the recombinant protein, we have constructed a
DNA encoding a truncated form of the MFα-l-Tg54 antigen wherein the sequence corresponding to residues 464 to 485 of the Tg54 antigen has been deleted. Thus, the Sall-BgHI DNA fragment from pNIV3414 was introduced in the pNIV3415 cut by Sail and BamHI to give the pNIV3422 (FIG.9a) The resulting plasmid was tiien digested by Hind III and EcoRI to recover a 1400 bp DNA fragment, blunt-ended and introduced in the blunt-ended BamHI site of the pRIT13145 (TCM97). The resulting expression plasmid, pNIV3423, contains, under the control of the ARG3 promoter, the sequence encoding the signal sequence of MFα-1 followed by residues 28 to 465 and 486 to 538 of the 54KD antigen (FIG.9b).
References 1. Margalit H„ Spouge J.L., Cornette J.L., Cease K.B., Delisi C, and Berzofsky J. A. (1987). Prediction of immunodominant helper T cell antigenic sites from the primary sequence. J. Immunol., 138, pp 2213-2229.
2. Rothbard J.B., and Taylor W.R. (1988). A sequence pattern common to T cell epitopes. EMBO J., 7, pp 93-100. 3. Claverie J-M., Kourilsky P., Langlade-Demoyen P., Chalufour-Prochnicka A., Dadaglio G., Tekaia F., Plata F., and Bouguerlet L. (1988). T-immunogenic peptides are constituted of rare sequence patterns. Use in the identification of T epitopes in die human imunodeficiency virus gag protein. Eur. J. Immunol., 18, pp 1547-1553.
4. Kent S.B. (1988). Chemical synthesis of peptides and proteins. Annu. Rev. Biochem., 57, pp 957-985.
5. Van Regenmortel M.H.V., Briand J.P., Muller S., and Plaue S. (1988) Syndietic polypeptides as antigens, ed. Elsevier, pp 95-130.
6. Saavedra R. and Herion P. (1991). Human T-cell clones against Toxoplasma gondii: production of interferon-gamma, interleukin 2, and strain cross-reactivity. Parasitol. Res., 77, 379 - 385.
7. Saavedra R., De Meuter F., Decourt J-L., and Herion P. Human T-cell clone identifies a potentially protective 54-kilodalton protein antigen of Toxoplasma gondii cloned and expressed in E. coli. J. Immunol. \__1, 1975 - 1982 (1991).
Claims
1. A polypeptide corresponding to residues 197 - 216 of the 54KD antigen of T_ g__ι__\u_
2. A polypeptide having the sequence TDPGDVVIEELFNRIPETSV.
3. A polypeptide according to Claim 1 or Claim 2 in substantially pure form.
4. A polypeptide corresponding to the 54KD antigen of T. gondii. characterised in that it is devoid of the transmembrane domain.
5. A compound comprising the polypeptide of any one of Claims 1 to 3 chemically bound to a heterologous molecule and having the ability to cause the formation of antibodies against T. gondii following internal administration to a human or animal.
6. A recombinant protein comprising me polypeptide of Claim 1 2, 3, or 4 fused to a heterologous antigen, which protein is capable of forming particles on expression in a suitable host.
7. A recombinant protein according to Claim 6 in which the heterologous antigen is derived from Hepatitis B surface antigen.
8. A recombinant protein according to Claim 6 or Claim 7 which is expressed in yeast.
9. A recombinant protein according to Claim 8 which consists of an initiation methionine followed by the sequence claimed in Claim 2, the 13 amino acids from the preS2 region of HBsAg and die 226 amino acids from the major HBsAg coding region.
10. A vaccine composition comprising an immunologically effective amount of a compound according to any one of Claims 1 to 9 admixed with a pharmaceutically acceptable carrier.
11. A method of preventing T. gondii infection in humans or animals by administering to a human or animal in need thereof an immunologically effective amount of a vaccine composition according to Claim 10.
12. A method of producing the 54 KD antigen of T. gondii or the T-cell epitope thereof (amino acids 197 - 216) by causing the product to be expressed from a host cell comprising a vaccinia virus or M. bovis - BCG, followed by purification of the product by conventional techniques.
13. A vaccinia infected cell or M. bovis - BCG host cell transfected or transformed with a vector comprising DNA encoding the 54KD antigen of T. gondii or the T-cell epitope thereof (amino acids 197 - 216).
14. A method for producing the 54 KDa antigen of T. gondii or a truncated form thereof by causing the product to be expressed from a CHO host cell followed by purification of die product by conventional techniques.
15. A CHO cell transfected with a vector comprising DNA encoding the 54 KDa antigen of T. gondii or a truncated form thereof.
16. A yeast cell transfected with a vector encoding the 54KDa antigen of T. gondii or a truncated form thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939308969A GB9308969D0 (en) | 1993-04-30 | 1993-04-30 | Novel compounds |
GB9308969 | 1993-04-30 | ||
GB9313797 | 1993-07-03 | ||
GB939313797A GB9313797D0 (en) | 1993-07-03 | 1993-07-03 | Novel compounds |
PCT/EP1994/001298 WO1994025594A2 (en) | 1993-04-30 | 1994-04-26 | Cloning, expression and vaccine composition corresponding to a peptide antigen of toxoplasma gondii |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0695356A1 true EP0695356A1 (en) | 1996-02-07 |
Family
ID=26302834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94915540A Withdrawn EP0695356A1 (en) | 1993-04-30 | 1994-04-26 | Cloning, expression and vaccine composition corresponding to a peptide antigen of toxoplasma gondii |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0695356A1 (en) |
JP (1) | JPH08512200A (en) |
WO (1) | WO1994025594A2 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9027728D0 (en) * | 1990-12-20 | 1991-02-13 | Smithkline Beecham Biolog | Novel protein |
IT1256575B (en) * | 1992-12-10 | 1995-12-11 | Cesalpino Andrea Fond | PROCEDURE FOR THE PREPARATION OF IMMUNOGENS CONSTITUTED BY EXOGENOUS ANTIGENS CAPABLE OF GENERATING NOT ONLY THE IMMUNE RESPONSE OF T HELPER LYMPHOCYTES, BUT ALSO AN EFFECTIVE RESPONSE OF CYTOTOXIC T LYMPHOCYTES; AND IMMUNOGENES SO OBTAINABLE. |
-
1994
- 1994-04-26 EP EP94915540A patent/EP0695356A1/en not_active Withdrawn
- 1994-04-26 JP JP6523864A patent/JPH08512200A/en active Pending
- 1994-04-26 WO PCT/EP1994/001298 patent/WO1994025594A2/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9425594A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO1994025594A3 (en) | 1995-06-01 |
JPH08512200A (en) | 1996-12-24 |
WO1994025594A2 (en) | 1994-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5114713A (en) | P. falciparum cs-peptides as universal t-cell epitope | |
US5759814A (en) | Expression of recombinant glycoprotein B from herpes simplex virus | |
JP4241846B2 (en) | Hybrid protein between CS and HBsAg derived from malaria parasite | |
US6306625B1 (en) | Method for obtaining expression of mixed polypeptide particles in yeast | |
US4722840A (en) | Hybrid particle immunogens | |
Rutgers et al. | Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum. | |
US20030175296A1 (en) | Chimaeric hepadnavirus core antigen proteins | |
Pachl et al. | Expression of cell-associated and secreted forms of herpes simplex virus type 1 glycoprotein gB in mammalian cells | |
NO167359B (en) | PROCEDURE FOR THE PREPARATION OF A VACCINE AGAINST INFECTION OF HEPATITIS B VIRUS. | |
US5928902A (en) | Hybrid protein between CS from plasmodium and HBsAg | |
Tuchscherer et al. | Total chemical synthesis, characterization, and immunological properties of an MHC class I model using the TASP concept for protein de novo design | |
JPH08502244A (en) | Immunomodulatory peptide | |
US5976544A (en) | Polypeptides and vaccines for Bordetellapertussis and method of use | |
JP3023997B2 (en) | Recombinant Coccidiosis Vaccine-5-7 Eimeria Surface Antigen | |
AU615451B2 (en) | Immunogenic recombinant yeast expression product and method for purifying it | |
CA2344993C (en) | Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus | |
EP0278941A1 (en) | Expression of the P. falciparum circumsporozoite protein by yeast | |
US6169171B1 (en) | Hybrid protein between CS from plasmodium and HBSAG | |
EP0695356A1 (en) | Cloning, expression and vaccine composition corresponding to a peptide antigen of toxoplasma gondii | |
EP0358485A2 (en) | Human rhinovirus peptides | |
EP0826050A1 (en) | Modified polypeptides for enhanced immunogenicity | |
AU604711B2 (en) | Novel vaccines | |
EP0322394A2 (en) | Expression of HIV proteins in E. coli and S. cerevisiae | |
PT87137B (en) | PROCESS FOR PREPARING THE RECOMBINANT YEAST EXPRESSION PRODUCT | |
IE910966A1 (en) | Plasmodium Sporozoite Antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951013 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 20001211 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20010622 |